Burstable Nutrition Team
Nutrition In-Focus
@burstable
Burstable News™ is a hosted solution designed to help businesses build an audience and enhance their AIO and SEO press release strategies by automatically providing fresh, unique, and brand-aligned business news content. It eliminates the overhead of engineering, maintenance, and content creation, offering an easy, no-developer-needed implementation that works on any website. The service focuses on boosting site authority with vertically-aligned stories that are guaranteed unique and compliant with Google's E-E-A-T guidelines to keep your site dynamic and engaging.
48 articles
Articles
Annovis Bio Secures FDA Meeting for Parkinson's Dementia Drug Development
Annovis Bio Inc. has secured a Type C meeting with the U.S. Food and Drug Administration scheduled for January 2026 to discuss the clinical pathway for buntanetap in Parkinson's disease dementia. The company also reaffirmed continued progress in its Phase 3 Alzheimer's trial, which remains in full regulatory alignment on de...
November 18, 2025Read more
Annovis Bio's Buntanetap Shows Promise in Halting Cognitive Decline in Parkinson's Patients with Alzheimer's Co-pathology
Annovis Bio Inc. released new findings from its Phase 3 early Parkinson's disease study demonstrating that buntanetap halted cognitive decline across all patients and delivered the strongest benefit in those with mild dementia and amyloid co-pathology. This subgroup represents approximately 25% of the study population and t...
November 17, 2025Read more
CNS Pharmaceuticals Reports Progress on Blood-Brain Barrier Drug Candidate for Glioblastoma
CNS Pharmaceuticals Inc. has reported third-quarter 2025 financial results while highlighting significant progress with its lead drug candidate TPI 287, a blood-brain barrier-permeable abeotaxane being developed for glioblastoma and other central nervous system tumors. The company's Phase 1 clinical data demonstrated potent...
November 17, 2025Read more
NRx Pharmaceuticals Reports Q3 2025 Progress in Suicidal Depression Treatments
NRx Pharmaceuticals, Inc. reported third-quarter 2025 results while highlighting substantial progress across its clinical pipeline, particularly for treatments targeting suicidal depression. The company noted its first revenue-generating activities alongside key regulatory advancements for both NRX-100 and NRX-101 programs....
November 17, 2025Read more
NanoViricides Reports Progress on Broad-Spectrum Antiviral NV-387 in Quarterly Filing
NanoViricides, Inc. has filed its Form 10-Q for the quarter ended September 30, 2025, highlighting significant progress on its lead drug candidate NV-387, a first-in-class broad-spectrum antiviral designed to resist viral escape by mimicking conserved sulfated proteoglycan receptors used by more than 90% of viruses. The com...
November 17, 2025Read more
GLP-1 Medications Show 50% Lower Mortality in Colon Cancer Patients, Study Finds
Recent research from UC San Diego revealed that colon cancer patients using GLP-1 medications such as Ozempic and Wegovy demonstrated a 50% lower mortality rate compared to those not taking these drugs. The findings suggest that medications already approved for specific clinical indications may have additional therapeutic b...
November 14, 2025Read more